London, UK – TrialValue, a pioneering platform developed by RHIEOS Ventures Ltd (UK), has announced the launch of its revolutionary human-augmented analytics intelligence budget prediction engine for clinical trials. This cutting-edge solution, originally developed in 2018 using machine learning algorithms, curated datasets, and real-world data, is designed to generate comprehensive trial budgets with minimal assumptions—bringing unprecedented speed, confidence, and accuracy to the clinical research financial landscape.

TrialValue’s budget prediction engine is the first of its kind, capable of generating full budgets backed by assurance that high-performance trials include actionable recommendations for optimization. By leveraging advanced analytics and intelligent modeling, TrialValue empowers clinical research stakeholders—including patients, patient groups, research sites, sponsors, service providers, and investors—to make informed financial decisions and execute value-enhancing transactions and collaborations.

Larry Ajuwon, Director of RHIEOS Ventures, heralds this innovation as “TrialValue Clinical R&D Financial Benchmarking’s new deal.” He further emphasizes the company's commitment to transforming financial planning in clinical trials: “Our mission at TrialValue is to provide financial solutions that ensure transparency, efficiency, and strategic decision-making, ultimately driving better outcomes for all participants in clinical research.”

With its ability to streamline budgeting and resource planning, TrialValue ensures that clinical development programs are executed with optimal financial efficiency, reducing delays and financial uncertainty in an increasingly complex industry landscape.

For more information, please contact:

Media Contact:
info@trialvalueapp.com
TrialValue
London, UK